Alnylam Pharmaceuticals (NASDAQ: ALNY) is one of 185 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Alnylam Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and risk.


This table compares Alnylam Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals -664.70% -46.94% -35.58%
Alnylam Pharmaceuticals Competitors -4,676.40% -578.44% -44.24%

Risk and Volatility

Alnylam Pharmaceuticals has a beta of 2.97, suggesting that its stock price is 197% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals’ competitors have a beta of 1.56, suggesting that their average stock price is 56% more volatile than the S&P 500.

Earnings and Valuation

This table compares Alnylam Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alnylam Pharmaceuticals $47.16 million -$410.10 million -23.40
Alnylam Pharmaceuticals Competitors $217.29 million -$39.39 million -62.34

Alnylam Pharmaceuticals’ competitors have higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Alnylam Pharmaceuticals and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals 3 3 14 1 2.62
Alnylam Pharmaceuticals Competitors 540 2428 6532 127 2.65

Alnylam Pharmaceuticals presently has a consensus price target of $129.40, suggesting a potential upside of 5.33%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.44%. Given Alnylam Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

88.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 50.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.3% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with's FREE daily email newsletter.